Iceland· IS-EU/1/14/928/001
Sylvant
A siltuximab product containing siltuximabum inn, registered in Iceland by Recordati Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Siltuximab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC11 (siltuximab), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 9 of them publish a price we can compare per daily dose
Siltuximab · ATC L04AC11
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Siltuximabum INN
- Manufacturer
- Recordati Netherlands B.V.
- Country
- Iceland (IS)
- ATC code
- L04AC11
- ATC class
- Siltuximab
- Defined daily dose
- 37 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
151 interactions on record for siltuximab.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Siltuximab · interactions on record
151 records
- 28 severe
- 116 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Siltuximab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandSYLVANTAbacus Medicine A/S
- SwitzerlandSylvant 100 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungMedius AG
- CzechiaSYLVANTRecordati Netherlands B.V., Schiphol-Rijk
- SpainSYLVANT 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRecordati Netherlands B.V.
- United KingdomSylvant 100mg powder for concentrate for solution for infusion vialsRecordati UK Ltd
- IrelandSYLVANT 100 mg powder for concentrate for solution for infusionEUSA Pharma (Netherlands) B.V.
- NorwaySylvantRecordati Netherlands B.V.
- PolandSylvantRecordati Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Sylvant
- Norway · Sylvant
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0ac72682-5145-4c66-93b7-e8df26f18797 GET /v1/drugs/0ac72682-5145-4c66-93b7-e8df26f18797?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L04AC11",
"marketed": false,
"strength": "100 mg",
"ma_number": "EU/1/14/928/001",
"substance": "Siltuximabum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "41795"
}See everything about siltuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.